Find a Clinical Trial
Filter
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)
Bladder cancer
All genders
18+
Recruiting now
Department of Medicine, Cancer Center
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Breast Cancer Database
Breast cancer
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer
Breast cancer
All genders
16+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
HER2 Negative Breast Cancer
Breast cancer
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Multi-spectral imaging
Ovarian cancer
Female
18-99
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Breast cancer
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)
Endometrial cancer
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center